Condition · 2 treatment paths
HER2-Positive Breast Cancer
HER2-positive breast cancer is a type of breast cancer whose cells carry too many copies of the HER2 gene, driving faster growth. It makes up around one in five breast cancers.
Send your imaging + plan. Board-reviewed opinion in 5–10 working days.
- Treatment paths
- 2Treatment paths
- Specialties
- 1Specialties
- Typical severity
- SevereTypical severity
About her2-positive breast cancer
What to know
It usually presents as a breast lump or change on screening mammography, sometimes with enlarged underarm lymph nodes. Biopsy confirms the cancer and tests for HER2, hormone receptors and grade, with imaging to stage it. Before targeted drugs HER2-positive disease was aggressive, but treatment has greatly improved outcomes.
Treatment combines surgery, either lumpectomy with radiotherapy or mastectomy, with chemotherapy and HER2-targeted drugs such as trastuzumab, often with pertuzumab, given before or after the operation for about a year. Hormone therapy is added when the tumour is hormone-receptor positive. Regular heart monitoring is needed during targeted therapy. Patients sometimes seek second opinions or treatment abroad.
Pre-flight workup
Tests to have already done
- Pathology report confirming HER2 status by immunohistochemistry (3+) or in situ hybridisation, with oestrogen receptor, progesterone receptor and Ki-67.
- Imaging reports: mammogram, ultrasound, MRI and, for larger or node-positive cancers, staging CT or PET.
- Biopsy or surgical pathology showing tumour size, grade, margins and lymph node status.
- An echocardiogram or MUGA scan with ejection fraction, since trastuzumab can affect the heart.
- Records of chemotherapy, trastuzumab doses and any response, plus genetic test results if done.
Second opinion
When to get a second look
- HER2 status is borderline or unclear and has not been confirmed by a second test.
- You are offered mastectomy and want to know whether chemotherapy and HER2 drugs first could allow breast conservation.
- You have residual disease after pre-operative treatment and further drug options are being discussed.
- You have heart problems or worry about heart risk with trastuzumab.
Talking to your doctor
Questions to ask
- How certain is my HER2 result, and what is my hormone receptor status?
- Should I have treatment before surgery to shrink the tumour?
- Which HER2-targeted drugs will I receive, and for how long?
- How will my heart be monitored during treatment?
- Could I have breast-conserving surgery, and will I need radiotherapy?
- What is the plan if cancer remains after pre-operative treatment?
Outlook
Realistic prognosis
HER2-positive breast cancer was once linked to a poor outlook, but HER2-targeted therapy has greatly improved survival, and most early-stage patients treated with chemotherapy and trastuzumab are cured. Outcome depends on stage, lymph node involvement, hormone receptor status and response to pre-operative treatment. Heart function must be monitored during treatment. Advanced disease can often be controlled for long periods with newer HER2-directed drugs.
01 · Specialties
Specialties that treat HER2-Positive
Diagnostic workup
Before you pick a hospital, get the workup right
Picking the right treatment is downstream of a complete diagnosis. Skip steps here and the destination surgeon usually re-orders them anyway — at higher cost and another week on the ground.
- Confirm the diagnosis on imaging or labs
For her2-positive breast cancer, plan on the workup your home doctor would order anyway — typically a recent specialist consult plus the imaging / labs the destination team will need to quote accurately. Anything older than 90 days usually gets re-done.
- See a oncology specialist locally first
An in-person clinical exam at home — even a single consult — costs little and dramatically improves the destination plan. Bring back: written impression, recommended procedure, surgical-risk class, and any contra-indications.
- Send us the file for a free second opinion
Two surgeons in our medical panel review the workup independently. They tell you whether they'd operate, watch, or refer — even if that means recommending against travel.
- Pick a path with timeline + cost in writing
Once a treatment is the right call, we line up 2–3 hospital options with itemized quotes, surgeon profiles, and a travel timeline. You hold the file — switch hospitals or step away at any point.
Where to be treated
HER2-Positive Breast Cancer treatment by destination
04 · FAQ
Common questions about her2-positive breast cancer
Is HER2-positive cancer more dangerous?
It grows faster than HER2-negative cancer, but HER2-targeted drugs have greatly improved outcomes, and many early cases are cured.
How long do I take trastuzumab?
Early-stage patients typically receive trastuzumab for about one year, alongside or after chemotherapy, with heart checks every few months.
Can trastuzumab affect my heart?
In some people it can weaken the heart muscle. This is monitored with echocardiograms, and it often improves if treatment is paused.
Do I still need hormone therapy?
If your cancer is also oestrogen receptor positive, hormone therapy is usually added for several years.
Clinical context
Working up her2-positive breast cancer properly
A condition like her2-positive breast cancer is rarely well-served by jumping straight to treatment shopping. The sequence below is what a oncology specialist would expect to see completed — and the absence of any step is the right cue to delay travel decisions.
Diagnostic workup, in sequence
- First-line clinical assessment
History, physical exam, and risk-factor review by a senior generalist or oncology specialist. Symptoms list, family history, prior workup notes, and current medication list should travel with the patient.
- Standard imaging + labs
Baseline blood work, condition-specific imaging (ultrasound / X-ray / MRI / CT — depending on indication), and ECG / pulmonary function as relevant. Bring digital copies of any prior imaging — saves repeat scans and the cost that goes with them.
- Specialist diagnostic workup
Procedure-specific tests — biopsy, cardiac catheterisation, endoscopy, or genetic / molecular profiling depending on the suspected diagnosis. Done at the centre that will treat, ideally, so results integrate cleanly into the treatment plan.
- Multidisciplinary review (where indicated)
Cancer, complex cardiac, transplant, and rare-disease cases should be reviewed by a multidisciplinary panel — surgical, medical, imaging, and pathology — before any treatment commits. Single-discipline plans for complex disease are a quality red flag.
When to escalate urgently
- Acute worsening of established symptoms — sudden chest pain, shortness of breath at rest, neurological deficit, severe bleeding, persistent high fever.
- Loss of consciousness, severe persistent vomiting, or any focal neurological event.
- Symptoms in the early hours of onset that fit a time-sensitive treatment window (stroke, MI, sepsis) — every hour costs outcome.
- If you are travelling internationally for treatment and develop these symptoms in transit, divert to the nearest emergency department; do not wait to reach the planned destination.
Before you book international travel
- Confirm your specific diagnosis is fully worked up before you commit to a treatment plan abroad. Travelling for the workup is fine; travelling for treatment without the workup done is not.
- Get your case reviewed remotely by the destination centre's team before you book flights — credible international patient programs review imaging + reports before they confirm the surgical plan.
- Bring a digital + physical copy of your full medical record: imaging on USB drive in DICOM format, labs in PDF, current medication list with dosages, allergies, and any prior surgical reports.
- Plan for longer recovery + post-discharge therapy continuation before you fly — the surgery itself is rarely the bottleneck.
- Confirm that follow-up imaging and any necessary in-person reviews can be done at home — a treatment plan that requires repeat international trips is more burdensome (and more expensive) than the headline procedure.
Methodology and editorial standards
This her2-positive breast cancer overview is written by the editorial team from published Oncology sources and lists 2 treatment options offered by hospitals on our network. The page shows its last-updated date. Clinical descriptions are editorial — your treating clinician confirms what's right for your specific case.
- Hospital data. Hospital details are compiled from public sources and hospital websites. Accreditation (JCI, NABH and others) is shown where we hold a record of it. Always ask the hospital for its current certificate.
- Doctor credentials. Qualifications, specialty and bio come from the doctor's hospital profile. Licence is checked against the national medical-council register only where the profile shows a "Licence verified" badge with a date.
- Prices. Price ranges are indicative, compiled from hospital price lists and packages and shown with the date last updated. The hospital's written quote is what you pay against.
- Clinical text. Written by the Medcasts editorial team from published clinical sources. Unless a named reviewer is shown on the page, it has not been reviewed by a doctor.
- Independence. Hospitals cannot pay to change their position on our pages.
HER2-Positive Breast Cancer
Continue evaluating her2-positive breast cancer care
Condition overview is one entry. These hubs route the same care decision via specialty, surgeon, treatment, and destination — including the doctors actively treating her2-positive breast cancer.
- Surgeons Doctors treating HER2-Positive Breast Cancer Volume-ranked specialists across all relevant specialties.
- Specialty Oncology hub Programs, surgeons, hospitals across oncology.
- Procedure Lumpectomy (Breast-Conserving Surgery) First-line treatment with success rates, recovery, hospital pricing.
- Procedure Targeted Therapy (Trastuzumab / Imatinib course) Alternative treatment path with cost and recovery data.
- Browse All 79 conditions Map condition → specialty → first-line treatment.
- Browse 9 destination countries Cost-of-care profiles, hospital programs, visa playbooks.
- Compare Hospital comparison Side-by-side accreditations, ratings, beds, and pricing.
- Compare Doctor comparison Surgeons compared on volume, fees, languages, video-consult availability.
- Tool Match-me triage Three questions, get a specialty + destination + 3-hospital shortlist.
- Tool Cost calculator Hospital-reported pricing across procedures × destinations.
- Action Free second opinion Independent panel review of your case in 48 hours — no charge.
Next step · HER2-Positive Breast Cancer
Free second opinion on your HER2-Positive case.
Share imaging and the current plan. Multidisciplinary board returns a written opinion within 5–10 working days — no obligation to travel.